Cobra Biomanufacturing has announced that the current Good Manufacturing Practice production of Scancell Holdings' SCIB1 DNA vaccine has been completed.
SCIB1 is being developed for the treatment of melanoma.
The vaccine has been developed using Scancell's ImmunoBody technology platform that overcomes the current limitations of most cancer vaccines by generating the high-avidity T-cells that kill cancer cells.
The final release of the product for SCIB1 clinical trials is anticipated mid-Q4 2009 and will be undertaken by Cobra's in-house QP.
